InMed Pharmaceuticals Inc. Q4 FY2021 earnings call

• BayMedica acquisition: Entered into definitive agreement, expected to close soon, brings rare cannabinoid expertise, manufacturing flexibility, and revenue stream. - IntegraSyn: Made yield improvements, facing potential supply chain issues with starting material, targeting pilot batch production. - Therapeutic programs: INM-755 Phase 2 trial on track, INM-088 preclinical progress. - Catalysts: BayMedica acquisition closing, Phase 2 trial commencement, glaucoma data publication, IntegraSyn scaling. - Share price: Aligned with cannabis market, company monitoring and increasing investor relations efforts.

BayMedica: Cumulative revenues in excess of $2.5 million since December 2019, with average 35% quarter-on-quarter growth for the year ended June 30, 2021. IntegraSyn: Achieved output levels of 2 grams per liter cannabinoid yield, then improved to 5 grams per liter, focusing on scaling up to larger batch sizes. Therapeutic programs: INM-755 Phase 2 clinical trial for EB on track to begin shortly; INM-088 preclinical progress with dose ranging studies completed and GLP studies setup ongoing.

• BayMedica acquisition closing expected in coming weeks to accelerate commercial activities. - Phase 2 clinical trial for INM-755 envisaged to commence shortly. - Glaucoma data from INM-088 program anticipated to be published in peer-reviewed journal. - IntegraSyn targeting pilot batch production and scaling to larger batches for commercial production.

• Supply chain issue with a starting material may impact the 1 kilogram batch production of IntegraSyn. - Share price performance is strongly aligned with cannabis company share prices, which have experienced significant decline.

Q: How should we think about revenues for fiscal year 2022 regarding the BayMedica acquisition?

A: Too early to provide exact guidance, but expect growth from historical as BayMedica's product has shown QoQ growth.

Q: How will the IntegraSyn business model play out?

A: Will be part of a suite of manufacturing technologies, with decision on pathway based on cannabinoid type, quantity, and quality needed.

Q: How long from completion of enrollment to data release for INM-755?

A: Enrollment takes up to 12 months, then several months for database lock, analysis, etc., likely 3-4 months after last patient completed.

Q: Timing for rollout of additional cannabinoids from BayMedica?

A: Too early for exact guidance, but expect additional launches over next few quarters.

Q: Timing for IND filing for INM-088?

A: Anticipated in the later half of calendar 2022 after completing IND-enabling toxicology studies and pre-IND meeting.